Synthetic inhaled drug prevents pneumonia in cancer patients
This article was originally published in Start Up
Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.
Register for our free email digests: